SCHEMBL384843

SCHEMBL384843

O=C1Cc2ncccc2O1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.34
CA9 Q16790 1/20 0.34
TDP2 O95551 1/20 0.33
NSD2 O96028 1/20 0.33
ABL1 P00519 1/20 0.33
PLCG1 P19174 1/20 0.33
CES1 P23141 1/20 0.33
PAX8 Q06710 1/20 0.33
RIN1 Q13671 1/20 0.33
MEN1 O00255 1/20 0.33
THRB P10828 1/20 0.33
BLM P54132 1/20 0.33
KMT2A Q03164 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
GAA P10253 1/20 0.33
PDE3B Q13370 1/20 0.32
PDE3A Q14432 1/20 0.32
NPC1 O15118 1/20 0.32
NCOA1 Q15788 1/20 0.32
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Imidazole SCHEMBL28620201 0.84 ALDH1A1 (0.37) NPC1
SCHEMBL24631376 0.77 PTPRC (0.37) TDP2NSD2ABL1PLCG1CES1
SCHEMBL29588358 0.74 MAOA (0.59) GAANPC1MAOAMAOB
SCHEMBL813060 0.74 MAOA (0.59) GAANPC1MAOAMAOB
SCHEMBL7850857 0.73 MAPK14 (0.34) TDP2NSD2ABL1PLCG1CES1
SCHEMBL2044670 0.73 PDE3B (0.36) TDP2NSD2ABL1PLCG1CES1
SCHEMBL15763902 0.71 MAOA (0.46) CA12CA9TDP1HPGDMAOA
Acetic Acid SCHEMBL5593975 0.70 MAOA (0.47) GAAMAOAMAOB
Quinoline SCHEMBL27357350 0.70 ALDH1A1 (0.52) MEN1KMT2ANPC1MAOAMAOB
SCHEMBL13028725 0.69 CA12 (0.36) CA12CA9TDP2NSD2ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116135858-B Furanopyridone compound and application thereof 中国科学院广州生物医药与健康研究院 2025-04-01 CN claimed
US-20250066360-A1 PYRIDINE-CONTAINING POLYCYCLIC DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2025-02-27 US claimed
EP-4464694-A1 PYRIDINE-CONTAINING POLYCYCLIC DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2024-11-20 EP claimed
CN-118525005-A Polycyclic derivative containing pyridine, preparation method and application thereof 上海翰森生物医药科技有限公司 2024-08-20 CN claimed
WO-2023134764-A1 PYRIDINE-CONTAINING POLYCYCLIC DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海翰森生物医药科技有限公司 2023-07-20 WO claimed
CN-116444493-A Derivative containing double parallel rings, preparation method and application thereof 上海翰森生物医药科技有限公司 2023-07-18 CN claimed
WO-2023088493-A1 FURO-PYRIDONE COMPOUND AND USE THEREOF 中国科学院广州生物医药与健康研究院 2023-05-25 WO claimed
CN-116135858-A Furanopyridone compound and application thereof 中国科学院广州生物医药与健康研究院 2023-05-19 CN claimed
CN-115943959-A Fluorine-containing pyridofuranone soluble liquid and preparation method thereof 上海生农生化制品股份有限公司 2023-04-11 CN claimed
EP-3644992-B1 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR MERCK SHARP & DOHME LLC (US) 2023-03-29 EP claimed
WO-2019000238-A1 5-(PYRIDIN-3-YL)OXAZOLE ALLOSTERIC MODULATORS OF M4 MUSCARINIC ACETYLCHOLINE RECEPTOR MERCK SHARP & DOHME CORP. (US) 2019-01-03 WO claimed
WO-2019005589-A1 5-(PYRIDIN-3-YL)OXAZOLE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR MERCK SHARP & DOHME CORP. (US) 2019-01-03 WO claimed
WO-2019005587-A1 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR MERCK SHARP & DOHME CORP. (US) 2019-01-03 WO claimed
WO-2019000236-A1 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF M4 MUSCARINIC ACETYLCHOLINE RECEPTOR MERCK SHARP & DOHME CORP. (US) 2019-01-03 WO claimed
EP-1791845-A2 FURANOPYRIDINE DERIVATIVES AS ACK1 AND LCK MODULATORS AMGEN INC. (US) 2007-06-06 EP claimed
WO-2006130160-A2 FURANOPYRIDINE DERIVATIVES AS ACK1 AND LCK MODULATORS AMGEN INC. (US) 2006-12-07 WO claimed
US-20060046977-A1 Furanopyridine derivatives and methods of use AMGEN INC. 2006-03-02 US claimed
US-4363664-A AQEOUS DISPERSION CONTAINING DYESTUFF PRECURSORS AND SURFACTANT STERLING DRUG INC. (US) 1982-12-14 US claimed
EP-0006772-B1 THIENO AND FUROPYRIDONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICINAL PREPARATIONS CONTAINING THEM OMNIUM FINANCIER AQUITAINE POUR L'HYGIENE ET LA SANTE - SANOFI (FR) 1981-11-04 EP claimed
EP-0006772-A1 Thieno and furopyridone derivatives, process for their preparation and medicinal preparations containing them OMNIUM FINANCIER AQUITAINE POUR L'HYGIENE ET LA SANTE - SANOFI (FR) 1980-01-09 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060046977-A1 Furanopyridine derivatives and methods of use LCK, NFATC1, MINK1 CA12 3850/4885CA9 2221/4885TDP2 1338/4885
US-20250066360-A1 PYRIDINE-CONTAINING POLYCYCLIC DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF MYD88, NOD1, LITAF CA12 4459/4885CA9 4592/4885TDP2 4007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.